

Cite this: *Chem. Sci.*, 2018, 9, 6685

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 17th April 2018

Accepted 1st July 2018

DOI: 10.1039/c8sc01743c

rsc.li/chemical-science

# Programmable one-pot synthesis of heparin pentasaccharides enabling access to regiodefined sulfate derivatives†

Supriya Dey<sup>a</sup> and Chi-Huey Wong<sup>b</sup>  <sup>ab</sup>

Heparin (H) and heparan sulfate (HS) belong to the glycosaminoglycan (GAG) family of oligosaccharides, and their sequences and sulfation patterns are known to regulate the functions of various proteins in biological processes. Among these, the 6-*O*-sulfation of HS/H contributes most significantly to the structural diversity and binding interactions. However, the synthesis of HS with defined sulfation patterns remains a major challenge. Herein, we report a highly efficient and programmable one-pot method for the synthesis of protected heparin pentasaccharides using thioglycoside building blocks with optimized relative reactivities to allow the selective deprotection and preparation of regiodefined sulfate derivatives.

## Introduction

Heparin (H) and heparan sulfate (HS) are linear and highly dispersed polyanionic molecules of glycosaminoglycans (GAGs). They are highly sulfated and composed of *D*-*N*-acetylglucosamine (GlcNAc) and either *D*-glucuronic acid (GlcA) or *L*-iduronic acid (IdoA) linked by repeating 1,4-glycosidic linkages,<sup>1</sup> and have been used as therapeutic agents for thrombosis and other cardiovascular diseases.<sup>2,3</sup> They are often found on the cell surface, in the basement membrane, and in extracellular or tissue matrices.<sup>4,5</sup> HS and heparin can be compared under the conventional definition as follows: (i) HS chains are typically composed of 50–250 disaccharide units with average molecular weights of 20–100 kDa, whereas heparin chains consist of repeating units with molecular weights ranging from 12 to 14 kDa;<sup>3</sup> (ii) the average number of *O*-sulfate groups is more uniform and there is a higher level of sulfation (2.5–3 sulfate groups/disaccharide) in heparin than in HS which has a lower level of sulfation (0.5–1.5 sulfate groups/disaccharide); (iii)  $\alpha$ -*L*-iduronates are predominantly present in heparin, whereas in HS, the uronates are the C-5 epimers of  $\beta$ -*D*-glucuronate; (iv) in heparin, *D*-glucosamine residues are mostly *N*-sulfated (80%), whereas in HS, they can be either *N*-acetylated or *N*-sulfated (30–60%). Overall, heparins are more sulfated and more charged than HS on the basis of structural properties.<sup>3c</sup> However, heparin and HS are less distinct than the

conventional description implies, as isolated polysaccharides from some organisms were found to be hybrid structures.<sup>3d</sup>

More than 100 heparin-binding proteins have been identified and more are expected to be discovered.<sup>6</sup> The biological properties of H/HS are mainly dictated by the sulfation pattern and the structure of the NS-domain,<sup>7</sup> but the mechanisms are poorly understood due to their complex structural patterns and the heterogeneity of the oligosaccharides. However, the binding of antithrombin III with a minimal sequence of HSs has been well studied, showing that the repeating tri-sulfated disaccharide unit IdoA2S-(1,4)-GlcNS6S-(1,4) is responsible for the anti-coagulant activity.<sup>8</sup> Recently, a structure–function relationship study of 3-*O*-sulfated HS has been reported with an emphasis on the conformation of the pyranose and the 2-*O*-sulfated IdoA. It was shown that the skew boat <sup>2</sup>S<sub>0</sub> conformation of 2-*O*-sulfated IdoA, located at the reducing end of the GlcNS3S6, is essential for the anticoagulant activity.<sup>9</sup> Thus, understanding the role of the sulfation pattern in H/HS can provide fundamental insights into the mechanism of molecular recognition and the activity of this class of molecule.<sup>10</sup>

The 6-*O*-sulfation of HS/H, especially that outside the NS-domains, contributes most significantly to the structural and functional diversity, and is the only modification step regulated by both the biosynthetic and post-synthetic processes.<sup>11</sup> The implications of 6-*O*-sulfation in HS–protein interactions have been associated with many biological functions, such as anti-coagulation, wound healing, embryonic development, inflammation and cancer progression.<sup>12,13</sup> Most recently, it was shown that H/HS saccharides interact with  $\beta$ -amyloid fibrils associated with Alzheimer's disease.<sup>14</sup> Furthermore, addition of a single 6-*O*-sulfate group at the non-reducing end of the [IdoA2S-GlcNS]<sub>6</sub> heparin oligosaccharide can switch its inhibitory properties, indicating the importance of the 6-*O*-sulfate group in HS/H chains.<sup>14a</sup>

<sup>a</sup>Department of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, 92037, USA

<sup>b</sup>The Genomics Research Center, Academia Sinica, No. 128, Academia Road, Section 2, Taipei, Taiwan. E-mail: ch Wong@gate.sinica.edu.tw

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc01743c

The chemical synthesis of H/HS oligosaccharides is challenging due to the laborious and repetitive steps of protection, uncontrolled stereoselective glycosylation, deprotection, and multiple purification processes, which give low efficiencies and low yields.<sup>15</sup> However, over the years, chemical and chemo-enzymatic<sup>16</sup> methodologies have been reported for the synthesis of heparin-like oligosaccharides,<sup>17–20</sup> and the heparin-based drugs fondaparinux<sup>21</sup> and idraparinux.<sup>22</sup> To overcome the disadvantages of multi-step oligosaccharide synthesis, we have developed a computer database, OptiMer, to store the relative reactivity values (RRVs) of many glycosyl donors/acceptors.<sup>23</sup> The database stores the type of sugar core, locations of unprotected hydroxyl groups, the directing natures of protecting groups, pictures of the compounds, and names and references of the compounds and also predicts the product stereochemistry. For a targeted oligosaccharide, the program searches the database to find the best synthetic route. Using this database, various oligosaccharides including a heparin pentasaccharide were rapidly assembled without work-up of intermediates or purification processes.<sup>24</sup> However, the overall yield in the one-pot synthesis of the heparin-like pentasaccharide was relatively low (20%) and this was not effective to access various regiodefined *O*-sulfates.<sup>24f</sup> Herein, we report an improved programmable one-pot method for the synthesis of a protected heparin pentasaccharide to allow access to various regiodefined *O*-sulfation patterns for the study of their binding and functions.

## Results and discussion

### Key intermediate synthesis

Eighteen key intermediates (Fig. 1) were designed with improved RRVs for the one-pot synthesis to access the 6-*O*-

sulfation patterns in heparin pentasaccharides. We used protecting groups to tune the reactivity of each building block to create significant differences in the RRVs. Regarding the case of the 2-aminosugars, the protecting group effect is in the following order: NHCbz > NHTroc > NPhth > N<sub>3</sub> > NHAc.<sup>24b,e</sup> Thus, we designed the synthetic route with the following considerations: (i) highly stereoselective  $\alpha$ -glycosylation influenced by the orthogonal protecting groups (N<sub>3</sub>, TBDPS, and OAc) by minimizing the electronic interactions with the developing positive charge in the transition state,<sup>25</sup> (ii) use of the *tert*-butyldiphenyl silyl (TBDPS) protecting group at O6 to stabilize the oxocarbenium ion by through-space electron donation<sup>26</sup> and to increase the RRV of donor 4, (iii) construction of stereoselective  $\beta$ -1,4-glycosidic linkages using the neighboring group participation effect of the *O*-2-benzoyl ester, (iv) selective installation of the 6-*O*-sulfate group with the aid of acetyl and levulinic protecting groups, (v) early-stage introduction of glucuronic acid at the disaccharide stage using 2,2,6,6-tetramethyl-1-piperidinyloxy/iodobenzene diacetate (TEMPO/BAIB)-mediated selective oxidation<sup>27</sup> of the 6-hydroxyl group, or late-stage introduction of glucuronic acid using *p*-methoxy benzyl ether as the primary hydroxyl protecting group of 6, (vi) selective introduction of the *N*-sulfate groups using the N<sub>3</sub> functionality, and (vii) use of benzyl ethers to mask the rest of the hydroxyl groups.

Our retrosynthetic analysis in Scheme 1 suggests that the pentasaccharides **1a** and **1b** could be generated from the fully protected pentasaccharides **3a** and **3b**, respectively, through sequential desilylation, 6-*O*-benzylation, saponification, *O*-sulfation, hydrogenolysis and *N*-sulfation (Scheme 1). The protected pentasaccharides **3a** and **3b** can be obtained from the programmable one-pot synthesis using the [1,2,2] approach with the building blocks shown in the scheme. Mono-saccharides (**4**, **9** and **13**) could be obtained from the *D*-glucosamine hydrochloride **16**. The remaining thioglycoside donors **10** and **11** (building block B) can be synthesized from penta-*O*-acetyl- $\beta$ -*D*-glucopyranoside **14**. The iduronic acid unit **12** can be accessed from the known diacetone *D*-glucose **15**,<sup>28</sup> and the disaccharide building blocks (**5**, **6**) could be obtained by NIS/TfOH-mediated glycosylation using the appropriate glycosyl donors and acceptors. We also synthesized the disaccharide acceptors **7a**, **7b**, **8a** and **8b** which contain the iduronic acid unit as building blocks for the synthesis of pentasaccharides with desirable 6-*O*-sulfation patterns. The syntheses of the mono-saccharide building blocks (Fig. 1) are described in the ESI.†

### Synthesis of disaccharides (BC and DE building blocks)

The synthesis of  $\beta$ -(1,4)-linked disaccharides (**19** and **20**) was performed using NIS/TfOH-mediated coupling of donors (**17** and **18**) with acceptor **9**, respectively. Subsequently, removal of the levulinyl groups of **19** and **20** using hydrazine monohydrate in the presence of AcOH : Py (2 : 3) afforded disaccharide acceptors **21** and **6** respectively, in excellent yields (Scheme 2). The TBDPS ether of **21** was readily deprotected using HF-Py to yield diol **22a**. The primary hydroxyl group in **22a** was selectively oxidized using 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) in





Fig. 1 Monosaccharide and disaccharide building blocks.






**Scheme 1** A retrosynthetic analysis of heparan pentasaccharide with regiodefined *O*-sulfation patterns. Fmoc = 9-fluorenylmethoxycarbonyl chloride, Ac = acetyl, Bn = benzyl, Bz = benzoyl, Lev = levulinyl, PMB = *p*-methoxybenzyl, TBDPS = *tert*-butyldiphenylsilyl, Me = methyl, Tol = 4-tolyl.

the presence of BAIB. The crude acid underwent subsequent esterification with methyl iodide in the presence of  $\text{KHCO}_3$  to afford glucuronic acid acceptor **5a** in 63% yield (Scheme 2). On the other hand, the 4,6-benzylidene protected glycosyl donor **10b** was coupled with acceptor **9** in the presence of NIS/TMSOTf to furnish disaccharide **22b** (Scheme 2). Hydrolysis of 4,6-*O*-benzylidene acetal using 80% AcOH led to the dihydroxy compound **23**. Selective oxidation of the primary hydroxyl group of **23** with TEMPO/BAIB and subsequent esterification with methyl iodide in the presence of  $\text{KHCO}_3$  gave disaccharide **5b** in 61% yield. For the synthesis of disaccharide IdoA-GlcN, the NIS/TfOH-mediated glycosylation of *L*-iduronic acid donor **12** and acceptors (**13a** and **13b**), followed by the *in situ* removal of the Fmoc group using  $\text{Et}_3\text{N}$ , was performed to furnish the disaccharides (building block DE) **7a** and **7b**, respectively, in excellent yields (Scheme 3). We also introduced an anomeric aminopentyl spacer to the disaccharide acceptors **8a** and **8b** through couplings of donor **12** and acceptors **24a** and **24b**, respectively (Scheme 3).

### One-pot synthesis


We wanted to test if glucuronic acid is better introduced as part of the disaccharide building block or through oxidation at the



**Scheme 2** Reaction conditions: (a) NIS, TfOH,  $\text{CH}_2\text{Cl}_2$ , AW 300 MS,  $-45\text{ }^\circ\text{C}$  to  $-30\text{ }^\circ\text{C}$ , 2 h; **19**: 76%, **20**: 73%; (b)  $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ , AcOH : Py (2 : 3), rt, 2 h; **6**: 90%, **21**: 88% (c) HF-Py, Py,  $0\text{ }^\circ\text{C}$  to rt, 12 h, 81%; (d) (i) BAIB, TEMPO,  $\text{CH}_2\text{Cl}_2$  :  $\text{H}_2\text{O}$  (2 : 1),  $0\text{ }^\circ\text{C}$  to rt, 2 h; (ii) Mel,  $\text{KHCO}_3$ , DMF, rt, 4 h,  $0\text{ }^\circ\text{C}$  to rt, **5a**: 63%, **5b**: 61% (two steps); (e) (i) NIS, TMSOTf,  $\text{CH}_2\text{Cl}_2$ , AW 300 MS,  $-20\text{ }^\circ\text{C}$  to  $0\text{ }^\circ\text{C}$ , 15 min; **22b**: 89%. (f) 80% AcOH,  $70\text{ }^\circ\text{C}$ , 3 h; **23**: 79%.


pentasaccharide stage. For the late stage oxidation to glucuronic acid, the disaccharide building block **6** was used in the one-pot synthesis of a pentasaccharide, followed by selective oxidation to an acid. Thus, the disaccharide building block **6** (RRV = 38.2) was used in the one-pot synthesis of the pentasaccharide **3c** which was then subjected to selective deprotection, oxidation and esterification to generate pentasaccharide **3a** in 42% yield. Similarly, another one-pot synthesis was performed using glucuronic acid containing disaccharide acceptor **5a** (RRV = 18.2) to generate the pentasaccharide **3a** in 54% yield (Scheme 4). Overall, the introduction of glucuronic acid at the disaccharide stage is more efficient than oxidation of the C-6 group to the carboxyl group after formation of the pentasaccharide motif. Next, to achieve the regioselective sulfation of partially protected heparin pentasaccharides, the unaltered donors (**4** and **5a**) and the disaccharide acceptor **7b** with appropriate protecting groups were used to yield **3b** in 48% yield.

We also introduced an anomeric aminopentyl spacer to the disaccharide acceptors **8a** and **8b** for the one-pot synthesis of



**Scheme 3** Reaction conditions: (a) (i) NIS, TfOH,  $\text{CH}_2\text{Cl}_2$ , AW 300 MS,  $-60\text{ }^\circ\text{C}$  to  $-30\text{ }^\circ\text{C}$ , 1 h; (ii)  $\text{Et}_3\text{N}$ , rt, 1 h.





Scheme 4 Reaction conditions: (a) NIS, TfOH,  $\text{CH}_2\text{Cl}_2$ , AW 300 MS,  $-45^\circ\text{C}$  to  $-25^\circ\text{C}$ ; (b) (i) DDQ,  $\text{CH}_2\text{Cl}_2$  :  $\text{H}_2\text{O}$  (10 : 1), rt, 1 h; (ii) BAIB, TEMPO,  $\text{CH}_2\text{Cl}_2$  :  $\text{H}_2\text{O}$  (2 : 1), rt, 2 h; (iii) MeI,  $\text{KHCO}_3$ , DMF,  $0^\circ\text{C}$  to rt, 4 h.

pentasaccharides **25a** and **25b**, respectively, using similar reaction conditions (Scheme 4) for the purpose of developing a glycan microarray.<sup>29</sup> We confirmed the stereochemistry of the newly formed glycosidic linkages in the protected pentasaccharide using C-H coupling constants, measured from the  $^{13}\text{C}$  coupled HMQC experiment.<sup>30</sup> In the case of pentasaccharide **3b**, the  $^1J_{\text{C-H}}$  coupling values were  $^1J_{\text{C-H}} = 178.15$  Hz ( $\alpha$ ), 176.06 Hz ( $\alpha$ ), 177.65 Hz ( $\alpha$ ), 172.56 Hz ( $\alpha$ ), and 163.3 Hz ( $\beta$ ), indicating the presence of four  $\alpha$ -linkages and one  $\beta$ -linkage.


### Diversification of heparin pentasaccharide sulfates: access to regiodefined 6-O-sulfation

To generate the heparin pentasaccharides with regiodefined 6-O-sulfation patterns, we used the pentasaccharides **3a** and **3b** for further modification through chemical sulfation and deprotection. The installation of 6-O- $\text{SO}_3$  failed in the presence of the TBDPS group, as the  $\text{SO}_3$  attacks the TBDPS ether groups and is inserted into the Si-O bond.<sup>31</sup> So, we replaced the TBDPS protecting group with the benzyl ether group in order to introduce O-sulfate. The silyl groups in **3a** and **3b** were removed using HF-Py to generate compounds **26a** and **26b** respectively with free hydroxyl groups at the non-reducing end. Benzylation of **26a** was attempted using a mixture of benzyl-2,2,2-trichloroacetimidate/TfOH or using NaH/BnBr. However, the decomposition of the starting material, hydrolysis of the methyl ester and acyl migration were observed under these reaction conditions. At this point, we came across the co-solvent promoted O-benylation using  $\text{Ag}_2\text{O}$ /BnBr reported by Hashimoto and co-workers.<sup>32</sup> Thus, O-benzylation of **26a** and **26b** were performed under Hashimoto's reaction conditions to furnish **27a** and **27b**, respectively, in excellent yields (Scheme 5).


On the other hand, the 6-O-Lev ester in **27b** was removed using hydrazine acetate in a mixture of MeOH and THF to give pentasaccharide **28** in a good yield. The co-solvent promoted O-benylation of **28** with  $\text{Ag}_2\text{O}$ /BnBr led to pentasaccharide **29** (Scheme 6).

Saponification of pentasaccharides **27a**, **27b** and **29** using LiOH/ $\text{H}_2\text{O}_2$  in THF, followed by NaOH in methanol, removed all ester functionalities.<sup>33</sup> To generate the GlcNS-GlcA2S-GlcNS6S-IdoA2S-GlcNS6S-OMe motif, the crude tetraol derivative was treated with  $\text{SO}_3\text{-Et}_3\text{N}$  at  $55^\circ\text{C}$  for 12 h to install two 6-O-sulfate and two 2-O-sulfate groups to generate **2a** (Scheme 5). Similarly, O-sulfation of the crude triol generated pentasaccharide GlcNS-GlcA2S-GlcNS6S-IdoA2S-GlcNS-OMe **2b** (Scheme 6).

The O-sulfated pentasaccharides **2a** and **2b** were converted to the protecting group free pentasaccharides in a two-step sequence: (i) catalytic hydrogenation in the presence of



Scheme 5 Synthesis of GlcNS-GlcA2S-GlcNS6S-IdoA2S-GlcNS6S-OMe (**1a**). Reaction conditions: (a) HF-Py, Py,  $0^\circ\text{C}$  to rt, 12 h, **26a**: 83%, **26b**: 85%; (b) BnBr,  $\text{Ag}_2\text{O}$ ,  $n\text{-Hex}$  :  $\text{CH}_2\text{Cl}_2$  (4 : 1), MS 4 Å,  $70^\circ\text{C}$ , sealed tube, 12 h, **27a**: 82%, **27b**: 78%; (c) (i) 1 M LiOH,  $\text{H}_2\text{O}_2$ , THF,  $-5^\circ\text{C}$  to rt, 8 h; (ii) 4 M NaOH, MeOH, rt, 18 h; (iii)  $\text{SO}_3\text{-Et}_3\text{N}$ , DMF,  $55^\circ\text{C}$ , 12 h, 75%; (d) (i)  $\text{H}_2$ , 20% Pd(OH) $_2$ /C, MeOH, 36 h, rt; (ii)  $\text{SO}_3\text{-Py}$ , 1 M NaOH, pH = 9.5,  $\text{H}_2\text{O}$ , rt, 38 h, 40% (5 steps).



**Scheme 6** Synthesis of GlcNS-GlcA2S-GlcNS6S-IdoA2S-GlcNS-OMe (**1b**). Reaction conditions: (a)  $\text{NH}_2\text{NH}_2 \cdot \text{AcOH}$ , THF : MeOH (1 : 1), 0 °C to rt, 2 h, 85%; (b) BnBr,  $\text{Ag}_2\text{O}$ , *n*-Hex :  $\text{CH}_2\text{Cl}_2$  (4 : 1), MS 4 Å, 70 °C, sealed tube, 12 h, 81%; (c) (i) 1 M LiOH,  $\text{H}_2\text{O}_2$ , THF, −5 °C to rt, 8 h; (ii) 4 M NaOH, MeOH, rt, 18 h; (iii)  $\text{SO}_3\text{--Et}_3\text{N}$ , DMF, 55 °C, 12 h, 77%; (d) (i)  $\text{H}_2$ , 20%  $\text{Pd}(\text{OH})_2/\text{C}$ , MeOH, 36 h, rt; (ii)  $\text{SO}_3\text{--Py}$ , 1 M NaOH, pH = 9.5,  $\text{H}_2\text{O}$ , rt, 38 h, 47% (5 steps).

$\text{Pd}(\text{OH})_2/\text{C}$  removed all benzyl ethers and reduced all azides to amines and (ii) selective *N*-sulfation was performed using  $\text{SO}_3\text{--pyridine}$  at pH 9.5 with 1 M NaOH (aq). Finally, the crude *O*- and *N*-sulfated product was purified using column chromatography with Sephadex G-25 using water as the eluent, and the desired fractions were pooled and passed through an ion exchange column of Dowex 50WX8Na<sup>+</sup>. The pure fractions were lyophilized to give the *N*-sulfated pentasaccharides **1a** (Scheme 5) and **1b** (Scheme 6), respectively.

## Conclusions

In summary, we have developed a new programmable one-pot strategy for the synthesis of protected heparin pentasaccharides, which can be selectively deprotected to enable the regioselective introduction of the sulfate groups. Using a set of designed thioglycoside building blocks with well-defined RRVs, a highly efficient synthesis of heparin pentasaccharide was achieved with improved overall yields. This method was applied

to generate heparin pentasaccharides with mono 6-*O*-sulfation (ring C) in **1b** and with double 6-*O*-sulfation (rings C and E) of **1a**. The highly efficient and stereoselective formation of  $\alpha$ -glycosidic linkages between the building blocks was achieved by a proper tuning of the protecting groups at the 6-hydroxyl positions during the one-pot synthesis. The use of silyl and acetyl groups at *O*-6 positions enhances the  $\alpha$ -selectivity by remote participation, and the use of the *tert*-butyldiphenylsilyl group at *O*-6 of the thioglycoside increases its reactivity (RRV) which seems to be the driving force for the high-yielding one-pot synthesis. The glucuronic acid unit is better introduced at the disaccharide stage as a building block than at the pentasaccharide stage through oxidation, and the selection of building blocks with significant differences in RRVs is important to eliminate the problem of self-coupling. This work provides a new set of building blocks and illustrates the programmable one-pot synthesis of complex heparin pentasaccharides with regiodefined sulfate patterns. Currently, we are using this strategy for the synthesis of other GAG derivatives to facilitate the structure–activity study of this class of molecule.

## Conflicts of interest


There are no conflicts to declare.

## Acknowledgements


The work was funded by the Academia Sinica and by the National Institutes of Health (AI072155) and the National Science Foundation (1664283).

## References

- 1 F. E. Poulain and H. J. Yost, *Development*, 2015, **142**, 3456; L. Fu, M. Suflita and R. J. Linhardt, *Adv. Drug Delivery Rev.*, 2016, **97**, 237; I. Capila and R. J. Linhardt, *Angew. Chem.*, 2002, **114**, 426.
- 2 I. Ahmed, A. Majeed and R. Powell, *Postgrad. Med. J.*, 2007, **83**, 575.
- 3 (a) D. Xu and J. Esko, *Annu. Rev. Biochem.*, 2014, **83**, 129; (b) R. J. Linhardt, *J. Med. Chem.*, 2003, **46**, 2551; (c) M. C. Z. Meneghetti, A. J. Hughes, T. R. Rudd, H. B. Nader, A. K. Powell, E. A. Yates and M. A. Lima, *J. R. Soc., Interface*, 2015, **12**, 20150589; (d) A. Parra, N. Veraldi, M. Locatelli, M. Fini, L. Martini, G. Torri, L. Sangiorgi and A. Bisio, *Glycobiology*, 2012, **22**, 248.
- 4 R. J. Linhardt and T. Toida, in *Carbohydrates in Drug design*, ed. Z. B. Witczak and K. A. Nieforth, Marcel Dekker, New York, 1997, ch. 4, p. 277.
- 5 (a) E. I. Oduah, R. J. Linhardt and S. T. Sharfstein, *Pharmaceuticals*, 2016, **9**, 38; (b) L. Kjellen and U. Lindahl, *Annu. Rev. Biochem.*, 1991, **60**, 443.
- 6 (a) A. Ori, M. C. Wilkinson and D. G. Fernig, *Front. Biosci.*, 2008, **13**, 4309; (b) H. E. Conrad, *Heparin Binding Proteins*, Academic Press, New York, 1998.



- 7 (a) A. Imberty, H. Lortat-Jacob and S. Perez, *Carbohydr. Res.*, 2007, **342**, 430; (b) I. Capila and R. J. Linhardt, *Angew. Chem.*, 2002, **41**, 391.
- 8 (a) X. Zhang, V. Pagadala, H. M. Jester, A. M. Lim, T. Q. Pham, A. M. P. Goulas, J. Liu and R. J. Linhardt, *Chem. Sci.*, 2017, **8**, 7932; (b) X. Zhang, Y. Xu, P.-H. Hsieh, J. Liu, L. Lin, E. P. Schmidt and R. J. Linhardt, *Org. Biomol. Chem.*, 2017, **15**, 1222.
- 9 Z. Wang, P.-H. Hsieh, Y. Xu, D. Thieker, E. J. E. Chai, S. Xie, B. Cooley, R. J. Woods, L. Chi and J. Liu, *J. Am. Chem. Soc.*, 2017, **139**, 5249.
- 10 (a) C. I. Gama, S. E. Tully, N. Sotogaku, P. M. Clark, M. Rawat, N. Vaidehi, W. A. Gaddard III, A. Nishi and L. C. Hsieh-Wilson, *Nat. Chem. Biol.*, 2006, **2**, 467; (b) J.-L. de Paz, C. Noti and P. H. Seeberger, *J. Am. Chem. Soc.*, 2006, **128**, 2766; (c) R. E. Masri, A. Seffouh, H. Lortat-Jacob and R. R. Vivès, *Glycoconjugate J.*, 2017, **3**, 285.
- 11 (a) E. Avizienyte, C. L. Cole, G. Rushton, G. J. Miller, A. Bugatti, M. Presta, J. M. Gardiner and G. C. Jayson, *PLoS One*, 2016, **11**, 1; (b) G. C. Jayson, S. U. Hansen, G. J. Miller, C. L. Cole, G. Rushton, E. Avizienyte and J. M. Gardiner, *Chem. Commun.*, 2015, **51**, 13846.
- 12 M. Petitou, B. Casu and U. Lindahl, *Biochimie*, 2003, **85**, 83.
- 13 (a) V. N. Patel, K. M. Likar, S. Zisman-Rozen, S. N. Cowherd, K. S. Lassiter, I. Sher, E. A. Yates, J. E. Turnbull, D. Ron and M. P. Hoffman, *J. Biol. Chem.*, 2008, **283**, 9308; (b) L. Wang, J. R. Brown, A. Varki and J. D. Esko, *J. Clin. Invest.*, 2002, **110**, 127.
- 14 (a) K. L. Stewart, E. Hughes, E. A. Yates, G. R. Akien, T.-Y. Huang, M. A. Lima, T. R. Rudd, M. Guerrini, S.-C. Hung, S. E. Radford and D. A. Middleton, *J. Am. Chem. Soc.*, 2016, **138**, 8328; (b) R. Schwörer, O. V. Zubkova, J. E. Turnbull and P. C. Tyler, *Chem.-Eur. J.*, 2013, **19**, 6817.
- 15 S. U. Hansen, G. J. Miller, M. J. Cliff, G. C. Jayson and J. M. Gardiner, *Chem. Sci.*, 2015, **6**, 6158 and references cited therein.
- 16 (a) W. Lu, C. Zong, P. Chopra, L. E. Pepi, Y. Xu, I. J. Amster, J. Liu and G.-J. Boons, *Angew. Chem., Int. Ed.*, 2018, **57**, 1; (b) J. Liu and R. J. Linhardt, *Nat. Prod. Rep.*, 2014, **31**, 1676; (c) R. Liu and J. Liu, *Biochemistry*, 2011, **50**, 4382; (d) H. J. Gijzen, L. Qiao, W. Fitz and C.-H. Wong, *Chem. Rev.*, 1996, **96**, 443.
- 17 (a) J.-C. Jacquinet, M. Petitou, P. Duchaussoy, I. Lederman, J. Choay, G. Torri and P. Sinaÿ, *Carbohydr. Res.*, 1984, **130**, 221; (b) P. Sinaÿ, J.-C. Jacquinet, M. Petitou, P. Duchaussoy, I. Lederman, J. Choay and G. Torri, *Carbohydr. Res.*, 1984, **132**, c5.
- 18 (a) H. N. Yu, J.-I. Furukawa, T. Ikeda and C.-H. Wong, *Org. Lett.*, 2004, **6**, 723; (b) J.-C. Lee, X.-A. Lu, S. S. Kulkarni, Y.-S. Wen and S.-C. Hung, *J. Am. Chem. Soc.*, 2004, **126**, 476; (c) J. D. C. Codée, B. Stubba, M. Schiattarella, H. S. Overkleeft, C. A. A. van Boeckel, J. H. van Boom and G. A. van der Marel, *J. Am. Chem. Soc.*, 2005, **127**, 3767; (d) M. M. L. Zulueta, S. Y. Lin, Y. T. Lin, C.-J. Huang, C.-C. Wang, C. C. Ku, Z. Shi, C.-L. Chyan, D. Irene, L.-H. Lim, T.-I. Tsai, Y.-P. Hu, S. D. Arco, C.-H. Wong and S.-C. Hung, *J. Am. Chem. Soc.*, 2012, **134**, 8988; (e) S. U. Hansen, G. C. Jayson, G. J. Miller and J. M. Gardiner, *Org. Lett.*, 2013, **15**, 88.
- 19 (a) S. Arungundram, K. Al-Mafraji, J. Asong, F. E. Leach III, I. J. Amster, A. Venot, J. E. Turnbull and G.-J. Boons, *J. Am. Chem. Soc.*, 2009, **131**, 17394; (b) C. Zong, R. Huang, E. Condac, Y. Chiu, W. Xiao, X. Li, W. Lu, M. Ishihara, S. Wang, A. Ramiah, M. Stickney, P. Azadi, I. J. Amster, K. W. Moremen, L. Wang, J. S. Sharp and G. J. Boons, *J. Am. Chem. Soc.*, 2016, **138**, 13059; (c) C. Zong, A. Venot, X. Li, W. Lu, W. Xiao, J.-S. L. Wilkes, C. L. Salanga, T. M. Handel, L. Wang, M. A. Wolfert and G.-J. Boons, *J. Am. Chem. Soc.*, 2017, **139**, 9534.
- 20 (a) Z. Wang, Y. Xu, B. Yang, G. Tiruchinapally, B. Sun, R. Liu, S. Dulaney, J. Liu and X. Huang, *Chem.-Eur. J.*, 2010, **16**, 8365; (b) G. Tiruchinapally, Z. Yin, M. H. El-dakdouki, Z. Wang and X. Huang, *Chem.-Eur. J.*, 2011, **17**, 10106; (c) S. B. Dulaney, Y. Xu, P. Wang, G. Tiruchinapally, Z. Wang, J. Kathawa, M. H. El-Dakdouki, B. Yang, J. Liu and X. Huang, *J. Org. Chem.*, 2015, **80**, 12265.
- 21 (a) C.-H. Chang, L. S. Lico, T.-Y. Huang, S. Y. Lin, C.-L. Chang, S. D. Arco and S.-C. Hung, *Angew. Chem., Int. Ed.*, 2014, **53**, 9876; (b) T. Li, H. Ye, X. Cao, J. Wang, Y. Liu, L. Zhou, Q. Liu, W. Wang, J. Shen, W. Zhao and P. Wang, *ChemMedChem*, 2014, **9**, 1071; (c) X. Dai, W. Liu, Q. Zhou, C. Cheng, C. Yang, S. Wang, M. Zhang, P. Tang, H. Song, D. Zhang and Y. Qin, *J. Org. Chem.*, 2016, **81**, 162.
- 22 G. Łopatkiewicz, S. Buda and J. Mlynarski, *J. Org. Chem.*, 2017, **82**, 12701.
- 23 Z. Zhang, I. R. Ollmann, X.-S. Ye, R. Wischnat, T. Baasov and C.-H. Wong, *J. Am. Chem. Soc.*, 1999, **121**, 734.
- 24 (a) J.-C. Lee, W. A. Greenberg and C.-H. Wong, *Nat. Protoc.*, 2006, **1**, 3143; (b) T. K.-K. Mong, H.-K. Lee, S. G. Durón and C.-H. Wong, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 797; (c) C.-H. Hsu, S.-C. Hung, C.-Y. Wu and C.-H. Wong, *Angew. Chem., Int. Ed.*, 2011, **50**, 11872; (d) C.-Y. Wu and C.-H. Wong, *Programmable one-pot glycosylation*, ed. B. Fraser-Reid and J. Cristóbal López, Springer, Berlin, Heidelberg, 2011, vol. 301, p. 223; (e) C.-Y. Ting, Y.-W. Lin, C.-Y. Wu and C.-H. Wong, *Asian J. Org. Chem.*, 2017, **6**, 1800; (f) T. Polat and C.-H. Wong, *J. Am. Chem. Soc.*, 2007, **129**, 12795.
- 25 (a) C. M. Pedersen, L. U. Nordstrøm and M. Bols, *J. Am. Chem. Soc.*, 2007, **129**, 9222; (b) Y. Hsu, X.-A. Lu, M. M. L. Zulueta, C.-M. Tsai, K.-I. Lin, S.-C. Hung and C.-H. Wong, *J. Am. Chem. Soc.*, 2012, **134**, 4549.
- 26 A. Imamura, N. Matsuzawa, S. Sakai, T. Udagawa, S. Nakashima, H. Ando, H. Ishida and M. Kiso, *J. Org. Chem.*, 2016, **81**, 9086.
- 27 L. J. van den Bos, J. D. C. Codée, J. C. van der Toorn, T. J. Boltje, J. H. van Boom, H. S. Overkleeft and G. A. van der Marel, *Org. Lett.*, 2004, **6**, 2165.
- 28 J. Tatai, G. Osztrovszky, M. Kajtár-Peredy and P. Fügedi, *Carbohydr. Res.*, 2008, **343**, 596.
- 29 (a) P.-H. Liang, C.-Y. Wu, W. A. Greenberg and C.-H. Wong, *Curr. Opin. Chem. Biol.*, 2008, **12**, 86; (b) C.-Y. Wu, P.-H. Liang and C.-H. Wong, *Org. Biomol. Chem.*, 2009, **7**, 2247.



- 30 (a) K. Bock, I. Lundt and C. Pederson, *Tetrahedron Lett.*, 1973, **13**, 1037; (b) K. Bock and C. Pederson, *J. Chem. Soc., Perkin Trans. 2*, 1974, 293.
- 31 A. Richter and D. Klemm, *Cellulose*, 2003, **10**, 133.
- 32 L. Wang, Y. Hashidoko and M. Hashimoto, *J. Org. Chem.*, 2016, **81**, 4464.
- 33 H. Lucas, J. E. M. Basten, T. G. van Dinther, D. G. Meuleman, S. F. van Aelst and C. A. A. van Boeckel, *Tetrahedron*, 1990, **46**, 8207.

